Cosmos Holdings

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Chicago, IL.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The conversion price represents a premium to market The conversion price represents a premium to market

Cosmos Holdings CEO Greg Siokas Converts an Additional $1.0 Million of Debt into Common Stock at $6.00 Per Share

First Phase Launches Sky Premium Life Products on Amazon and eBay; Second Phase Launch Includes Brick & Mortar Stores

Cosmos Holdings Signs Exclusive Distribution Agreement with Mediprovita GbR for Launch of Sky Premium Life Products in Germany and Austria

CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today announced that it has appointed finance veteran Alexi Papaconstantinou to the Company's Advisory Board.

Cosmos Holdings Appoints Finance Veteran Alexi Papaconstantinou to its Advisory Board

Cosmos Holdings CEO Greg Siokas Converts $3.0 Million of Debt into Common Stock at $6.00 Per Share

CHICAGO, May 18, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the first quarter ended March 31, 2021.

Cosmos Holdings Provides First Quarter 2021 Business Update; Reports 89% Year-Over-Year and 60% Sequential Increase in Nutraceutical Business

Marks First Step in Global E-Commerce Strategy; Reaffirms Plans to Enter New European and Global Markets in 2021 Marks First Step in Global E-Commerce Strategy; Reaffirms Plans to Enter New European and Global Markets in 2021

Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon UK

CHICAGO, April 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM ), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the full year ended December 31, 2020.

Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020

King Eros supplement formula developed to improve sexual health and men's libido

Cosmos Holdings Launches Proprietary King Eros and Queen Venus Supplements for Enhanced Libido

New proprietary formula for the symptomatic relief of pain and irritated sore throat

Cosmos Holdings Launches Mosept-Oral Antiseptic Spray Designed to be Effective Against Bacteria and Certain Viral Pathogens

New Proprietary Dietary Supplement Contributes to Normal Bone and Cartilage Health and Joint Flexibility

Cosmos Holdings Launches Osteodome in EU

CHICAGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the company") (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, today announced the launch of a new, proprietary enhanced dietary supplement, Bodyguard, a targeted action formula for strengthening the immune system and reducing fatigue.

Cosmos Holdings Launches New Proprietary Enhanced Dietary Supplement

Company Began Trading as OTCQX: COSM on November 25, 2020 Company Began Trading as OTCQX: COSM on November 25, 2020

Cosmos Holdings Announces December 4th Virtual Bell Ringing to Open Trading on the OTCQX Best Market

CHICAGO, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the company") (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, today announced it has qualified to trade on the OTCQX® Best Market; the company has upgraded to OTCQX from the OTCQB® Venture Market and begins trading today on OTCQX under the symbol “COSM.” U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Cosmos Holdings Begins Trading on the OTCQX® Best Market

News for Cosmos Holdings Stock (COSM)